This phase I trial tests the safety and effectiveness of stereotactic body radiation therapy (SBRT) followed by 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in treating patients with large well-differentiated grade 1-2 digestive system neuroendocrine tumors that cannot be removed by surgery (unresectable). SBRT is a type of external radiation therapy that uses special equipment to position a patient and precisely deliver radiation to tumors in the body. The total dose of radiation is divided into smaller doses given over several days. This type of radiation therapy helps spare normal tissue. 177Lu-DOTATATE is a radioactive drug. It binds to a protein called somatostatin receptor, which is found on some neuroendocrine tumor cells. 177Lu-DOTATATE builds up in these cells and gives off radiation that may kill them. It is a type of radioconjugate and a type of somatostatin analog. Giving PRRT after SBRT may reduce the chances of the disease returning or getting worse, compared to the standard treatment of PRRT alone.

Start Date01 Sep 2025

Sponsor / Collaborator

Emory University

[+1]

CTR20252063

/ RecruitingPhase 1/2

一项在新诊断的广泛期小细胞肺癌（ES-SCLC）患者中评估 [177Lu]Lu-DOTA-TATE联合卡铂、依托泊苷和阿替利珠单抗诱导治疗及阿替利珠单抗维持治疗的安全性和疗效的Ib/II期剂量探索研究

[Translation] A phase Ib/II dose-finding study evaluating the safety and efficacy of [177Lu]Lu-DOTA-TATE combined with carboplatin, etoposide, and atezolizumab induction therapy and atezolizumab maintenance therapy in patients with newly diagnosed extensive-stage small-cell lung cancer (ES-SCLC)

本研究旨在确定 [177Lu]Lu-DOTA-TATE联合卡铂、依托泊苷和阿替利珠单抗在该疾病中的安全可耐受剂量，并评估该联合治疗与卡铂、依托泊苷和阿替利珠单抗联合治疗相比的初步疗效。本研究对于评估此类侵袭性癌症参与者的新的潜在治疗选择至关重要。

[Translation]

This study aims to determine a safe and tolerable dose of [177Lu]Lu-DOTA-TATE in combination with carboplatin, etoposide, and atezolizumab in this disease and to evaluate the preliminary efficacy of this combination compared with carboplatin, etoposide, and atezolizumab. This study is critical in evaluating new potential treatment options for participants with this aggressive cancer.

Start Date28 Aug 2025

Sponsor / Collaborator

Advanced Accelerator Applications (Italy) Srl

[+3]

NCT06955169

/ Not yet recruitingPhase 2IIT

MOMENTUM-1: A Multicenter, Randomized, Open-Label, Phase II Study of [177LU]LU-DOTATATE in Adults With Progressive Intracranial Grade 1-3 Meningioma

This is an open-label, multicenter, randomized, phase 2 clinical study to evaluate the efficacy of [177Lu]Lu-DOTATATE in patients with progressive grade 1-3 intracranial meningioma.

Start Date01 Aug 2025

Sponsor / Collaborator

Novartis Pharmaceuticals Canada, Inc.

100 Clinical Results associated with Lutetium Dotatate LU-177

100 Translational Medicine associated with Lutetium Dotatate LU-177

100 Patents (Medical) associated with Lutetium Dotatate LU-177

1,135

Literatures (Medical) associated with Lutetium Dotatate LU-177

01 Dec 2025·Journal of Gastrointestinal Cancer

Mixed Neuroendocrine and Non-neuroendocrine Tumor of Pancreato-Biliary Origin Treated Successfully with Peptide Receptor Radionuclide Therapy

Article

Author: Navalkissoor, Shaunak ; Luong, Tu Vinh ; Krell, Daniel ; Paterson, Anna ; Caplin, Martyn ; Shekhda, Kalyan Mansukhbhai

PURPOSE:

Mixed neuroendocrine and non-neuroendocrine neoplasms (MiNENs) are rare neoplasms composed of morphologically distinguishable neuroendocrine (NE) and non-neuroendocrine components, each representing at least 30% of the tumor volume. The NE component must be substantiated by immunohistochemistry. MiNENs generally have a poor prognosis, with a more aggressive component dictating overall survival and prognosis. Owing to its rarity, there are no specific validated treatment guidelines available for these tumors, and they are generally treated with surgery if possible. However, surgically unresectable or advanced tumors are generally treated with chemotherapy.

METHODS:

We report a case of an elderly woman who was referred to the neuroendocrine tumor (NET) unit following incidental findings of liver lesions found on cardiac magnetic resonance imaging (MRI) performed for an asymptomatic heart murmur. Histology from the liver biopsy revealed MiNEN with up to 60% grade 2 (Ki67: 19%) well-differentiated NET and up to 30% well-differentiated to moderately differentiated adenocarcinoma of possible pancreato-biliary origin; intrahepatic ductal primary could not be excluded. Her 18-fluoro-deoxyglucose positron emission tomography (FDG-PET) revealed no FDG-avid lesions, and a ⁶⁸Gallium 1,4,7,10-tetraazacyclododecane-tetraacetic acid Tyr3-octreotate (⁶⁸ Ga-DOTATATE)-PET scan revealed multiple areas of intensely DOTATATE-avid liver lesions. Due to the absence of any primary imaging findings, the patient was diagnosed with MiNEN of possible pancreato-biliary origin.

RESULTS:

She was started on lanreotide 120 mg every 28 days for 6 months, with no response to the treatment. Subsequently, the patient was treated with four cycles of ¹⁷⁷Lutetium-DOTATATE (Lutathera®) peptide receptor radionuclide therapy (PRRT). She tolerated the treatment well, with no significant side effects. MRI at the end of treatment revealed a partial response to treatment.

CONCLUSION:

PRRT is currently not used in treatment protocols for the management of MiNENs; however, it could be considered a treatment option in patients with MiNENs, where there is a predominant component of well-differentiated NETs with ⁶⁸ Ga-DOTATATE avid lesions.

01 Nov 2025·NUCLEAR MEDICINE AND BIOLOGY

Alternative production of Lead-203: Optimizing production, purification, and radiolabelling for enhanced theranostic applications

Article

Author: Guertin, Arnaud ; Dufour, Héloïse ; Kamalakannan, Keerthana ; Brelet, Fabien ; Audouin, Nadia ; Nigron, Etienne ; Briand, Katalin ; Dureau, Remy ; Vidal, Aurélien ; Bozovic, Nicolas ; Galichet, Lou ; Tarinas, Maryne ; Sounalet, Thomas ; Haddad, Ferid ; Prezeau, Tony

INTRODUCTION:

this study investigates the production of Lead-203 (²⁰³Pb) using a deuteron beam and demonstrates its application with DOTATATE for diagnostic imaging of neuroendocrine tumours (NETs) thanks to its γ-ray emissions well-suited for SPECT imaging. ²⁰³Pb presents a high potential in nuclear medicine, as it is the imaging counterpart of part of Lead-212 (²¹²Pb), a radionuclide with an alpha-emitting decay chain used for targeted alpha therapy.

METHODS:

Enriched Thallium-205 (²⁰⁵Tl) was electrodeposited onto a gold substrate using a custom-made PEEK cell, with a platinum rod as the auxiliary electrode. The electrodeposition was conducted at a controlled temperature and stirring speed, with reverse pulse potentials applied to obtain a smooth and dense deposit. The ²⁰⁵Tl deposit was then irradiated with deuteron beams at 31 MeV to produce ²⁰³Pb. Chemical separation was performed using two columns containing Pb resin. The first column (150 mg resin) was used to remove ²⁰⁵Tl for further recycling and the second column (60 mg resin) was employed to obtain ²⁰³Pb in 1 M ammonium acetate at pH 5 ensuring high purity and specific activity. Radiolabelling of DOTATATE with ²⁰³Pb was conducted in a modified acetate buffer, and the radiochemical purity and stability were assessed using HPLC and TLC. The stability of [²⁰³Pb]Pb-DOTATATE was evaluated over a period of up to 120 h.

RESULTS:

the electrodeposition process, conducted over 8 h, yielded a reproducible ²⁰⁵Tl deposit with an average thickness of 37.7 ± 3.2 μm, which remained stable during irradiation. The chemical separation process achieved a ²⁰³Pb purity exceeding 99 % in 1 M ammonium acetate at pH 5, with a specific activity surpassing 3783 TBq/g for an integrated beam current of 175 μAh at calibration time (EOB + 32 h). The radiochemical separation yield during the process was 80.5 %. Radiolabelling of DOTATATE with ²⁰³Pb showed a high radiochemical purity (99.1 %) and a stability over 96 h, demonstrating the feasibility of using [²⁰³Pb]Pb-DOTATATE for clinical applications.

CONCLUSION:

Our results support the use of ²⁰³Pb produced using deuteron beam as valuable tools in the advancement of personalized nuclear medicine therapies. The high purity and specific activity of ²⁰³Pb, achieved through dual Pb resin purification process, along with its effective radiolabelling with DOTATATE at high yield and long stability, underscore its potential for clinical use in diagnostic imaging, especially in neuroendocrine tumours.

01 Nov 2025·COLLOIDS AND SURFACES B-BIOINTERFACES

Naphthalene-containing octreotide radioligand elevates selectivity and radionuclide therapy for somatostatin receptor 2-positive tumor

Article

Author: Guo, Jiakun ; Zhong, Zhiyuan ; Zhao, Xingyu ; Xu, Bin ; Meng, Fenghua ; Sun, Juan ; Wang, Guanglin ; Yang, Jiangtao ; Tao, Lei

Peptide receptor radionuclide therapy (PRRT) with proven targeting ability has emerged as a new paradigm for clinical tumor therapy. The selective binding of octreotide to somatostatin receptor 2 (SSTR2) renders the successful development of ¹⁷⁷Lu-DOTATATE for SSTR2-positive neuroendocrine tumor patients. Here, we find that naphthalene-containing octreotide radioligand (OCT(naph)) induces elevated tumor uptake and radionuclide therapy for SSTR2-positive tumor over DOTATATE. ¹⁷⁷Lu-OCT(naph) demonstrated high radiochemical purity and radiostability, and increased binding affinity to human serum albumin, which led to prolonged blood circulation time and a peak accumulation of 20.8 ± 3.2 %ID/g, 1.6-fold of that for ¹⁷⁷Lu-DOTATATE, in SSTR2⁺ HCT-116 tumor. A single injection of ¹⁷⁷Lu-OCT(naph) at 7.4 MBq while induced no apparent toxicity effectively suppressed tumor growth, significantly outperforming ¹⁷⁷Lu-DOTATATE. Overall, ¹⁷⁷Lu-OCT(naph) with optimized albumin binding appears as a potentially better radionuclide therapy for SSTR2-positive tumors.

298

News (Medical) associated with Lutetium Dotatate LU-177

24 Sep 2025

·www.globenewswire.com

ITM and TerThera Sign Supply Agreement for Medical Radioisotope Terbium-161

Garching / Munich, Germany, and Breda, the Netherlands, September 24, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and TerThera BV, a leading provider of GMP-grade Terbium-161, today announced a supply agreement for non-carrier-added (n.c.a.) Terbium-161 (Tb-161), a novel medical radioisotope with distinct chemical properties and emerging potential in radiopharmaceutical therapy. Under the terms of the agreement, TerThera will supply Good Manufacturing Practice (GMP)-compliant n.c.a. Tb-161 to ITM to support the development of its Terbium-based pipeline candidates, complementing ITM’s established manufacturing capabilities in cooperation with the Paul Scherrer Institute (PSI).“Driving innovation across isotopes, targeting molecules and cancer indications keeps ITM at the forefront of the rapidly evolving radiopharmaceutical industry,” said Dr. Andrew Cavey, CEO of ITM. “We see strong potential in Terbium-161 as a critical new isotope for targeted radiopharmaceutical therapy, and our partnership with TerThera will allow us to advance its use in our pipeline. With supply of Terbium-161, we are well-positioned to harness its radiation properties to deliver meaningful advances for people living with cancer.”Currently, Tb-161-based radiopharmaceuticals are being clinically investigated for various types of cancers. Tb-161 is gaining attention in the radiopharmaceutical field for its unique emission profile. Like Lu-177, it emits medium-range beta particles and has a similar half-life. However, Tb-161 also emits low-energy Auger and internal conversion electrons, delivering highly localized radiation that can effectively target isolated cancer cells and micro-metastases with minimal off-target effects. “As industry interest in Terbium-161 grows, a safe and sustainable supply of this radionuclide is crucial to support the development of new treatment options and strategies and we see this as our core mission,” added Philippe van Overeem, CEO of TerThera. “ITM is a true innovator in the dynamic radiopharmaceutical field and we look forward to supplying them with our GMP-grade Terbium-161 as they advance their pipeline candidates and make progress in bringing the benefit of this valuable isotope to patients.” About ITM Isotope Technologies Munich SEITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply of medical radioisotopes. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including multiple Phase 3 studies, combining the company’s high-quality radioisotopes with a range of targeting molecules. By leveraging our two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life. www.itm-radiopharma.com About TerTheraTerThera is a radionuclide production-focused company based in The Netherlands. The founders and staff of TerThera have decades of experience in the nuclear medicine industry and are highly dedicated to bringing the innovative radionuclide Terbium-161 (Tb-161) to the clinic. TerThera is building a global platform including GMP production facilities in Europe, USA and Asia to meet the growing demand for radionuclides in RLT. ITM ContactCorporate CommunicationsKathleen Noonan/Julia WestermeirPhone: +49 89 329 8986 1500Email: communications@itm-radiopharma.com Investor RelationsBen OrzelekPhone: +49 89 329 8986 1009Email: investors@itm-radiopharma.comTerThera Contactsupport@terthera.com Attachment 20250924_ITM and TerThera Sign Supply Agreement for Medical Radioisotope Terbium-161

Phase 3License out/inRadiation Therapy

10 Sep 2025

·www.einpresswire.com

Nanopharmaceutics Announces Presentation of National Cancer Institute sponsored Phase I Study with Triapine at ESMO 2025

Phase I Study with Triapine + Lutetium Lu 177 Dotatate in patients with progressive well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) TRON Group Inc. (OTCMKTS:TGRP) ALACHUA, FL, UNITED STATES, September 10, 2025 / EINPresswire.com / -- Nanopharmaceutics, Inc., a clinical-stage pharmaceutical development company, today announced a presentation of the National Cancer Institute (NCI) sponsored Phase I Study 10388 (NCT04234568) “Testing the Addition of an Anti-cancer Drug, Triapine , to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors” in an oral presentation at the European Society for Medical Oncology (ESMO) Congress, held from October 17-21, 2025 in Berlin, Germany. The data will be presented on the October 20th Mini oral session: NETs and endocrine tumours “1709MO - Multi-center NCI-sponsored phase 1 study of triapine in combination with 177Lu-dotatate in patients with well-differentiated gastroenteropancreatic neuroendocrine tumours (GEP-NETs)” at the 2025 European Society of Medical Oncology (ESMO) Congress by Aman Chauhan, MD, Associate Professor of Medical Oncology, Leader of Neuroendocrine Tumor Program and Co-Director of Theranostics Program, University of Miami Sylvester Comprehensive Cancer Center. This study was sponsored by the National Cancer Institute (NCI), part of National Institutes of Health, and conducted by the NCI funded Experimental Therapeutics Clinical Trials Network (ECTCN). The end of patient recruitment was recently announced for a NCI-sponsored randomized phase 2 trial 10558 (NCT05724108) “Testing the Effectiveness of an Anti-cancer Drug, Triapine ® , When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors” currently underway at 14 sites across the United States. This 94 patient phase II trial recently passed the pre-planned interim safety review and interim futility assessment and is awaiting primary endpoint maturity. Both studies are being performed under a Cooperative Research and Development Agreement (CRADA) between NCI and Nanopharmaceutics and conducted by ECTCN. About Triapine ® Triapine ® is s synthetic heterocyclic carboxaldehyde thiosemicarbazone with potential antineoplastic activity being studied in the treatment of cancer. It is a type of ribonucleotide reductase inhibitor. Also called 3-aminopyridine-2-carboxaldehyde thiosemicarbazone and 3-AP, Triapine ® inhibits the enzyme ribonucleotide reductase, resulting in the inhibition of the conversion of ribonucleoside diphosphates to deoxyribonucleotides necessary for DNA synthesis. About Nanopharmaceutics, Inc. Nanopharmaceutics, Inc. is a clinical-stage specialty pharmaceutical company developing oral, topical, and injectable products for cancer, central nervous system (CNS) disorders, and infectious diseases. Nanopharmaceutics is focused on formulation development aimed at improving drug absorption and stability. Nanopharmaceutics is a subsidiary of TRON Group Inc. (OTC:TGRP). James D Talton Nanopharmaceutics, Inc. +1 386-401-6304 info@nanopharmaceutics.com Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Phase 2Phase 1Clinical Result

10 Sep 2025

·www.prnewswire.com

C-Ray Therapeutics Supports Mednovo's Phase III Clinical Trial with First Patient Dosed for Lutetium [177Lu] Oxodotreotide Injection

CHENGDU, China, Sept. 10, 2025 /PRNewswire/ -- August 22, 2025, Mednovo Group Co., Ltd. ("Mednovo") announced that the first patient has been successfully dosed in its Phase III clinical trial of Lutetium [177Lu] Oxodotreotide Injection, a Class 3 targeted radiotherapeutic drug. As the exclusive clinical supply and manufacturing partner, C-Ray Therapeutics delivered end-to-end support for this milestone, including technology transfer, clinical batch production, quality release, and logistics. Leveraging China's first fully automated radiopharmaceutical production line built to global cGMP standards, C-Ray ensured the trial began on schedule. The company's philosophy—high quality, cost efficiency, and first-time-right production—underpinned its execution. Lutetium [177Lu] Oxodotreotide Injection targets somatostatin receptors and is primarily indicated for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Entering Phase III represents a pivotal step for the program, requiring production processes and quality controls that meet near-commercial standards. C-Ray's cGMP manufacturing capabilities and globally compliant quality system provided a solid foundation for reliable clinical supply. Since the project was accepted by China's Center for Drug Evaluation (CDE), C-Ray has worked closely with Mednovo's clinical schedule, efficiently completing raw material release, technology transfer, production, testing, and nationwide logistics to ensure timely first-patient dosing. Looking ahead, C-Ray will continue supporting Mednovo's multi-center trial with its patented, internationally compliant cold-chain packaging for radiopharmaceuticals and its integrated land-air logistics network. A Mednovo representative commented that C-Ray Therapeutics is a vital partner for their Lutetium [177Lu] Oxodotreotide Injection program. Their professional expertise, efficiency, and cGMP-compliant automated production line ensured the stable, high-quality supply of clinical materials for this Phase III trial. They look forward to advancing this program together. To date, C-Ray has successfully supported more than 50 CRDMO (Contract Research, Development, and Manufacturing Organization) projects across the full lifecycle—from early-stage R&D to clinical and commercial supply. With a 28,000 m² cGMP-compliant R&D and manufacturing base and a global radionuclide supply chain, C-Ray continues to deliver high-quality, efficient, and fully compliant solutions for pharmaceutical partners worldwide. About Mednovo Mednovo was established on January 1, 2011, as a diversified large-scale group company integrating R&D, production, sales, and investment& financing, with a dedicated focus on the healthcare industry. Since 2021, the group has adopted a strategy of "in-house R&D + acquisitions + equity investments" to establish multiple medical device projects, diversifying its portfolio and realizing its grand technological strategic vision for the industry. Starting with minimally invasive interventional sales, Mednovo has built a nationwide sales and service network. The group adheres to a dual approach of independent R&D and technology introduction, initially establishing an R&D, production, and operational system with internationally advanced standards. With a deep focus on global markets, the group actively seeks cutting-edge international technologies that address unmet market needs. Through an innovative industry collaboration model of "financial investment + sales partnership," Mednovo works hand-in-hand with leading players, using investment to drive projects and projects to fuel development. Currently, the group holds 39 medical device registration certificates, covering multiple specialized fields such as drug-coated balloon products, microwave ablation therapy products, cryoablation therapy products, tumor interventional embolization therapy products, neurointerventional products, and assisted reproductive consumables. Additionally, the group is expanding into the nuclear medicine sector, with several innovative nuclear medicine products under development. This has formed a dual-driven development strategy of "devices + nuclear medicine," dedicated to advancing the healthcare industry through innovative technologies. About C-Ray Therapeutics C-Ray Therapeutics is a leading radiopharmaceutical CRDMO in China, providing one-stop solutions from process development and IND application to clinical supply and commercial manufacturing. The company operates a 28,000 m² world-class cGMP production base and GLP-like pre-clinical research facilities. To date, C-Ray has delivered more than 50 CRDMO projects, among these, 6 projects are at the IND and IND-enabling stages, 7 have advanced to investigator-initiated trials (IIT), and 2 have entered the clinical supply phase. The company also plays an active role in developing and integrating the global radionuclide supply chain, including securing scarce isotopes such as Actinium-225. To date, C-Ray has successfully supported the development of 14 Ac-225–based labeling programs. Through its industry-academia-research-application platform, C-Ray aims to drive innovation, overcome technical barriers, and accelerate the clinical translation of diagnostic and therapeutic radiopharmaceutical solutions, positioning itself as a benchmark enterprise in global radiopharmaceutical development. SOURCE C Ray Therapeutics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 3Acquisition

100 Deals associated with Lutetium Dotatate LU-177

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	V10XX04	DB13985

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Somatostatin Receptor-Positive Neuroendocrine Tumor	Japan	Novartis Pharma KK	23 Jun 2021
Somatostatin Receptor-Positive Neuroendocrine Tumor	Japan	FUJIFILM Toyama Chemical Co., Ltd.	23 Jun 2021
SSTR positive Gastro-Enteropancreatic Neuroendocrine Tumor	European Union	Advanced Accelerator Applications SA	26 Sep 2017
SSTR positive Gastro-Enteropancreatic Neuroendocrine Tumor	Iceland	Advanced Accelerator Applications SA	26 Sep 2017
SSTR positive Gastro-Enteropancreatic Neuroendocrine Tumor	Liechtenstein	Advanced Accelerator Applications SA	26 Sep 2017
SSTR positive Gastro-Enteropancreatic Neuroendocrine Tumor	Norway	Advanced Accelerator Applications SA	26 Sep 2017

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Gastro-Enteropancreatic Neuroendocrine Tumor	NDA/BLA	United States	Curium Pharma UK Ltd.	09 Jul 2024
Advanced Neuroendocrine Neoplasm	Phase 3	China	Sinotau Pharmaceutical Group	11 Jun 2024
Neuroendocrine Carcinoma	Phase 3	China	Sinotau Pharmaceutical Group	11 Jun 2024
Neuroendocrine Tumors	Phase 3	China	Sinotau Pharmaceutical Group	11 Jun 2024
Advanced Pancreatic Neuroendocrine Tumor	Phase 3	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	06 Jul 2023
Carcinoid Tumors, Intestinal	Phase 3	United States	Advanced Accelerator Applications SA	06 Sep 2012
Carcinoid Tumors, Intestinal	Phase 3	Belgium	Advanced Accelerator Applications SA	06 Sep 2012
Carcinoid Tumors, Intestinal	Phase 3	France	Advanced Accelerator Applications SA	06 Sep 2012
Carcinoid Tumors, Intestinal	Phase 3	Germany	Advanced Accelerator Applications SA	06 Sep 2012
Carcinoid Tumors, Intestinal	Phase 3	Italy	Advanced Accelerator Applications SA	06 Sep 2012

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO2025	Not Applicable	Olfactory Esthesioneuroblastoma First line \| Second line somatostatin receptor (SSTR)	-	177Lu-dotatate	dcvztstdht(oodnahueuc) = wifgdhovyp pdswpaoohj (mffbxmdjgn, 8.29 - NE)	Positive	30 May 2025
NCT03972488 (NETTER-2, CTgov)	Phase 3	Gastro-Enteropancreatic Neuroendocrine Tumor	226	Sandostatin LAR+Lys-Arg+Octreotide long acting repeatable+Lutathera (Lutathera® Plus Octreotide LAR 30 mg (Investigational Arm))	gnliloogwr(mfpgouomsm) = dbbboahcnl exoucnpfoj (tmovprgjtc, wrpbulmdhc - vcswoyalwy) View more	-	10 Oct 2024
NCT03972488 (NETTER-2, CTgov)	Phase 3	Gastro-Enteropancreatic Neuroendocrine Tumor	226	octreotide (Octreotide LAR 60 mg (Control Arm))	gnliloogwr(mfpgouomsm) = hqxhpawjas exoucnpfoj (tmovprgjtc, ovuysvqyfn - raiddsuhch) View more	-	10 Oct 2024
NCT02743741 (OZM-067, ASTRO2024)	Not Applicable	-	33	177Lu-DOTATATE	rmpasiskfo(ydetbtqxwl) = skquxmarkn yntnbkgrgh (tmofwnrsht, 0.87) View more	Positive	01 Oct 2024
NCT02743741 (OZM-067, ASTRO2024)	Not Applicable	-	33	68Ga-DOTATATE	rmpasiskfo(ydetbtqxwl) = eqimnvzjgk yntnbkgrgh (tmofwnrsht, 0.87) View more	Positive	01 Oct 2024
ASTRO2024	Phase 2	Neuroendocrine Tumors	195	177 Lu-DOTATATE (177Lu-D >880 mCi)	rngfbpcxwy(nlegrqzmgf) = aswttkbqwz bvfqjbanyk (qltewsrova, 90 - 100) View more	Negative	01 Oct 2024
ASTRO2024	Phase 2	Neuroendocrine Tumors	195	177 Lu-DOTATATE (177Lu-D 800 Â± 10%)	rngfbpcxwy(nlegrqzmgf) = yjwikniytq bvfqjbanyk (qltewsrova, 73 - 100) View more	Negative	01 Oct 2024
ASTRO2024	Phase 2	Meningioma somatostatin receptors	20	177Lu-Dotatate 7.4 GBq	ebgejoouyo(rqlvceyrxx) = gpofogzhnb dvtjfzshgb (lvwykxbmod, 52 - 94) View more	Positive	01 Oct 2024
ASTRO2024	Not Applicable	Gastro-Enteropancreatic Neuroendocrine Tumor	-	<sup>177</sup>Lu-DOTATATE	ajopfcdgcv(efempkoyza) = stesrtokgf hcwhfmftgv (cxtmwgrqte )	-	01 Oct 2024
Biospace Manual	Phase 2	Meningioma	20	Lutathera	olyvvywgqx(vobgdocupc) = upvqbawqlr zhjmnupdgv (lwchlxljkt ) View more	Positive	30 Sep 2024
EANM2024	Not Applicable	Bone metastases	77	177Lu-DOTATATE PRRT	kdknymrini(jgjivlifqp) = lrqqsvsltt yibtmlbnch (ggywgnkrik ) View more	-	27 Sep 2024
Lu-Dotatate and capecitabine combination treatment (EANM2024)	Phase 2	Neuroendocrine Tumors somatostatin receptor-positive	111	177Lu-DOTATATE and capecitabine combination therapy	eywtramnnn(pumpvyxqjg) = umjdfqfwdt vpegcbadju (yirdfumyqg ) View more	Negative	27 Sep 2024
	Phase 2	Neuroendocrine Tumors somatostatin receptor-positive	111	177Lu-DOTATATE	eywtramnnn(pumpvyxqjg) = gjwgvphnlo vpegcbadju (yirdfumyqg ) View more	Negative	27 Sep 2024
EANM2024	Not Applicable	Gastro-Enteropancreatic Neuroendocrine Tumor	20	Standard 177Lu-RLT regimen (7.4 GBq infusions every 8 weeks)	kikznckyim(gqartegsjp) = one case of myelodysplasia pnxdhxnjst (nirgyxbkdg )	Positive	27 Sep 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis